CIK 0001841387
- Emerging growth company
Candel Therapeutics, Inc.
Sign in to watch- Ticker
- CADL
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 522214851
- Phone
- +1 617-916-5445
- Business address
- 117 KENDRICK STREET, SUITE 450, NEEDHAM, MA, 02494
- 4 Grant or award Chief Technology Officer acquired 104,516 shares (grant or award)
- 4 Grant or award Chief Medical Officer acquired 88,822 shares (grant or award)
- 4 Grant or award Chief Scientific Officer acquired 112,790 shares (grant or award)
- 4 Grant or award Chief Financial Officer acquired 125,717 shares (grant or award)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4/A Open-market buy Director bought 27,000 shares at an average $1.89 ($51,108)
Page 7 of 11 · 202 filings